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Background: Hemostatic alterations occur during the development of cancer. Plasma D-dimer is a hypercoagulability
and fibrinolytic system marker that is increased in patients with various solid tumours. The aim of this study was to
evaluate the hemostatic status of nasopharyngeal carcinoma (NPC) patients by assessing plasma D-dimer levels to
investigate its value as a prognostic marker.
Methods: We retrospectively analysed 717 patients with nasopharyngeal carcinoma, and we applied Cox regression and
log-rank tests to assess the association of D-dimer levels with disease-free survival (DFS), distant metastasis-free survival
(DMFS), and overall survival (OS). D-dimer levels were measured using a quantitative D-dimer latex agglutination assay.
Results: Using the 3rd quartile values (0.8 μg/L) as the optimal cut-offs, we found that patients with high D-dimer levels
have a shorter 3-year DFS, (79%, 95%CI (73.1–84.9)) vs. (69%, 95%CI (59.2–78.8)), DMFS (87%, 95%CI (83.1–90.9)) vs.
(77%, 95%CI (69.2–84.8)), and overall survival (82%, 95%CI (76.1–87.9)) vs. (76%, 95%CI (66.2–85.8)). Multivariate analysis
revealed that pre-treatment D-dimer levels and EBV DNA were significant independent factors for DFS, DMFS, and OS
in NPC patients. Subgroup analyses indicated that the plasma D-dimer levels could effectively stratify patient prognosis
for early cancer, advanced stage cancer, and patients with EBV DNA ≥4000 copies/ml.
Conclusions: High D-dimer levels were associated with poor disease-free survival, distant metastasis-free survival,
overall survival, and increased risk of mortality in NPC patients. Prospective trials are required to assess the prognostic
value of D-dimer levels.
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unless otherwise stated.United States [1-3]. Radiotherapy regimens are currently
the primary treatment strategy for NPC patients. Al-
though the TNM staging system [4] is currently the
most powerful prognostic factor for NPC, patients with
the same stage and similar treatment regimens have
variable clinical outcomes. The expression of several
specific biological markers have been used to provide
additional prognostic information for NPC patients,
including epidermal growth factor receptor [5], serum lac-
tate dehydrogenase (LDH) [6], C-reactive protein (CRP)
[7], and plasma Epstein-Barr virus DNA (EBV DNA) [8].
Several studies have investigated pre-treatment EBV DNA,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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tion in the clinic [8-10].
Several studies have suggested an association between
a more aggressive cancer phenotype and hypercoagula-
bility [11,12]. Interestingly, in the absence of venous
thromboembolism (VTE), the systemic activation of
blood coagulation and procoagulant changes in the
hemostatic system are frequently been observed in can-
cer patients [13,14]. Patients with cancer and hypercoa-
gulation have a higher risk of venous thrombosis and a
poor prognosis [15]. It has been reported that many
increased or decreased coagulation factors contribute to
cancer growth, progression and metastasis [16]. The
plasma D-dimer is a stable end product of fibrin degrad-
ation, and it is a useful biomarker for predicting venous
thromboembolism (VTE) in cancer patients [17]. In-
creased D-dimer levels are related to tumour stage,
tumour prognosis and lymph node involvement. Add-
itionally, D-dimer levels are a negative prognostic indi-
cator for several malignancies, including breast [18],
colorectal [19], lung [20], and prostate cancer [21]. Ele-
vated D-dimer levels may reflect multifactorial interactions
between carcinoma growth and the hemostatic-fibrinolytic
system in malignancy. However, the clinical significance
of D-dimer in nasopharyngeal carcinoma has not been
established.
The purpose of this study was to analyse the prognos-
tic value of plasma D-dimer levels in patients with NPC
and evaluate the correlation between pre-treatment
plasma D-dimer levels and clinical-pathological parame-
ters. The results of our study will help predict NPC pro-




The principal inclusion criteria were as follows: (1) biopsy-
proven primary NPC, no radiotherapy, chemotherapy,
or oncologic surgery history, and an ECOG of 0 to 2;
(2) patient age ≥18 years; (3) adequate hematologic,
renal, and hepatic function (white blood cell count
of ≥ 4000/μ L, platelet count of ≥100000/UL, serum cre-
atinine clearance ≥ 50 mL/min, total serum bilirubin con-
centration < 1.5 mg/dL); and (4) available follow-up data.
The following exclusion criteria were used for our study:
(1) patients who had a history of venous thrombosis or
anticoagulation therapy within 3 months before treatment;
(2) patients with previous or coexisting cancer other than
NPC; (3) pregnancy and lactation; or (4) stroke or neuro-
surgery within 6 months.
Between January 2008 and December 2011, a total
of 717 consecutive non-distant-metastatic NPC patients
(average age of 47, ranging from 29 to 71 years old)
were enrolled at Sun Yat-sen University Cancer Center(Guangzhou, China). During the same time period, 126
healthy volunteers (average age of 45, ranging from 19
to 75 years old) who submitted to D-dimer testing as
part of a routine physical examination in our hospital
were enrolled as the control group. This retrospective
study was approved by the Clinical Research Ethics
Committee of the Sun Yat-sen University Cancer Center,
and all the participants provided written informed con-
sent before treatment.
The routine staging patient work-up included the fol-
lowing clinical examinations of the head and neck region:
magnetic resonance imaging scans from the suprasellar
cistern to the collarbone, fibre optic nasopharyngoscopy,
chest radiography, abdominal sonography, whole-body
bone scan or whole body FDG PET/CT. All patients
were restaged according to the seventh American Joint
Committee on Cancer (AJCC) TNM staging manual. All
clinical records and magnetic resonance images were
independently reviewed by 2 radiologists (X.W.L and
L.Z.L.) to minimise heterogeneity in restaging. Before
treatment, the following baseline clinical data were col-
lected from the medical records and information system
at the study institute: sex, age, WBC counts, neutrophil
counts, haemoglobin (HGB), platelet counts, LDH, CRP,
hereditary NPC, smoking status, PS by Eastern Coopera-
tive Oncology Group (ECOG), and the presence of con-
current diseases, such as cardiovascular disease, diabetes
and chronic hepatitis.
Treatment delivery
One hundred and sixty-seven (23.3%) patients were treated
with conventional two-dimensional (2D-CRT) or three-
dimensional conformal radiotherapy (3D-CRT), and the
remaining 550 (76.7%) patients were treated with intensity-
modulated radiotherapy (IMRT). Details of the radiother-
apy techniques used at the Sun Yat-sen University Cancer
Center were reported in a previous study [22,23]. Six hun-
dred and forty (91.3%) patients with stage II–IV disease re-
ceived concurrent platinum-based chemotherapy.
A stratified multi-therapeutic protocol was used to
treat patients. Radiation therapy alone was used for stage
I disease, and radiation with concurrent platinum-based
chemotherapy was used to treat stage II disease [24].
Concurrent chemoradiotherapy, with or without neoadju-
vant or adjuvant chemotherapy, was used for advanced-
stage disease (stages III and IV). Neoadjuvant or adjuvant
chemotherapy consisted of cisplatin with 5-fluorouracil or
cisplatin with taxane administered every 3 weeks for 2 or
3 cycles [25]. The concurrent chemotherapy regimen con-
sisted of cisplatin given on weeks 1, 4, and 7 of RT, or
weekly cisplatin. All the patients at the study institution
were treated according to the principle of treatment for
NPC patients at Sun Yat-sen University Cancer Center,
Guangzhou, China.
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A 3 mL fasting blood sample was collected before treat-
ment of NPC patients and on the day of physical exam-
ination for the healthy volunteers. The sample was
processed within 3 hours of collection, and the plasma
was stored at −70 to −80°C until analysis. D-dimer values
were measured by a latex-enhanced immunoturbidi-
metric assay (Sekisui Medical Co., Ltd., Tokyo, Japan)
using a Sysmex CA 7000 (Sysmex Corp., Kobe, Japan)
analyser in the clinical hospital laboratory. The results
were obtained using a standard curve prepared according
to the manufacturer’s instructions, and the inter-assay
imprecision (coefficient of variation) was < 10%.
EBV DNA, VCA-IgA, and EA-IgA measurement
As described in previous studies [26-28], patient plasma
EBV DNA concentrations were routinely measured by
q-PCR before treatment. A cut-off level of 4000 copies/ml
was chosen to define low and high EBV DNA levels
because this threshold has previously been shown to be
prognostic in NPC patients using the same measure-
ment system [10,29]. EBV-specific VCA/IgA antibodies
and EBV-specific EA/IgA antibodies were measured using
a previously described immunoenzymatic assay [30].
Clinical outcomes assessment and patient follow-up
The primary endpoint of our study was disease-free
survival (DFS). The secondary endpoints were distant
metastasis-free survival (DMFS) and overall survival
(OS). We calculated DFS from the date of the first NPC
diagnosis to the date of the first relapse at any site, death
from any cause or the date of the last follow-up visit.
DMFS was calculated from the date of the first NPC
diagnosis to the date of distant relapse or patient censor-
ing at the date of the last follow-up. OS was calculated
from the date of the first NPC diagnosis to the date of
death from any cause or patient censoring at the date of
the last follow-up. After treatment was completed, pa-
tients were evaluated at 3-month intervals for the first
3 years and every 6 months thereafter.
Statistical analysis
The characteristics of the patients were divided into
quartiles and described by median values and the 25th-
75th percentiles (due to non-normally distributed con-
tinuous variables). Mann–Whitney U-tests were used to
compare continuous variables in different subgroups.
The Spearman correlation test was used to examine the
association between D-dimer levels and other variables.
Survival curves were calculated by the Kaplan-Meier
method, and univariate analyses were performed using
the log-rank test. Variables that reached a p-value
of ≤ 0.05 in the univariate analysis were entered into multi-
variate analyses. All statistical calculations were performedusing SPSS 17.0 for Windows (Chicago, IL), and a P < 0.05
was considered statistically significant.
Results
Baseline characteristics and distribution of D-dimer level
in the study population and subgroups
The pretreatment characteristics of the 717 NPC pa-
tients are listed in Table 1. The median follow-up was
31 months (IQR, 24–42). Forty-eight patients developed
locoregional recurrences, and 85 patients developed
distant metastases. Of these patients, 16 patients had
both local and distant metastases. The plasma D-dimer
level was higher in NPC patients than healthy volunteers
(P < 0.001, Figure 1), with the values of 0.50 (25th-75th
percentile: 0.3-0.8) and 0.4 ug/mL (25th-75th percentile:
0.3-0.5), respectively. The median D-dimer level was higher
in patients with distant metastasis compared to patients
without distant metastasis (P = 0.002, Figure 1), with values
of 0.60 (25th-75th percentile: 0.4-1.0) and 0.50 (25th-75th
percentile: 0.3-0.7), respectively. The D-dimer level was
higher in patients with plasma EBVDNA ≥ 4000 copies
than in patients with EBVDNA < 4000 copies (P = 0.002,
Figure 1), with values of 0.50 (25th-75th percentile: 0.3-0.9)
and 0.50 (25th-75th percentile: 0.3-0.7), respectively.
Patients who died during the observation period had
significantly higher D-dimer levels at baseline than pa-
tients who were alive at the end of the study or the last
follow-up: 0.6 (25th-75th percentile: 0.4-0.925) and 0.5
(25th-75th percentile: 0.3-0.7), respectively (P = 0.002,
Figure 1). A Spearman correlation analysis further dem-
onstrated that plasma D-dimer levels correlated with age,
serum CRP level, LDH level, EBV DNA level, tumour
TNM stage, and distant metastasis (Additional file 1:
Table S1).
D-dimer levels and probability of survival
For the Kaplan-Meier analysis, patients were categorised
into the following four groups according to their D-dimer
levels: the 1st group (D-dimer levels ranging from mini-
mum to 1st quartile of D-dimer levels in the total cohort
population: 0.0-0.3 μg/mL), 2nd group (D-dimer levels
from 1st quartile to 2nd quartile: 0.3-0.5 μg/mL), 3rd
group (D-dimer levels from 2nd quartile to 3rd quartile:
0.5-0.8 μg/mL) and 4th group (D-dimer levels from 3rd
quartile to maximum: 0.8-37.2 μg/mL). Additional file 1:
Figure S1 shows the Kaplan-Meier estimates for DFS,
DMFS and OS according to D-dimer levels. Elevated
D-dimer levels were significantly associated with shorter
DFS, DMFS and OS (log-rank trend test: P < 0.001).
Using the 1st group as a reference, the unadjusted
hazard ratio (HR) for DFS, DMFS, and OS of the top
quartiles were 2.26 (95% CI, 1.38-3.70), 2.99 (95% CI,
1.63-5.48), and 3.06 (95% CI, 1.70-5.51), respectively. A
similar trend of adjusted HR was observed for DFS,







NPC patients (n = 717) Control (n = 126)
Age at study entry 47 (39–47) 45 (39–53)
Sex
Male 533 (74.3) 102 (81)
Female 184 (25.7) 24 (19.0)
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< 6.7 362 (50.5)
≥6.7 355 (49.5)
Neutrophil, 109/L
< 4.0 359 (50.2)
≥4.0 358 (49.8)
HGB, g/L
< 143.8 359 (50.1)
≥ 143.8 358 (49.9)
PLT, 109/L
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Abbreviations: ECOG Eastern Cooperative Oncology Group, 2DRT two-
dimensional radiotherapy, 3DCRT three-dimensional conformal radiotherapy,
IMRT intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA
level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000
copies/ml, VCA viral capsid antigen. IgA immunoglobulin A, EA early antigen,
LDH Serum Lactate Dehydrogenase Levels, CRP high-sensitivity C-reactive
protein, WBC White blood cell, HGB haemoglobin, PLT platelet,
NPC nasopharyngeal carcinoma.
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D-dimer for disease-free, distant metastasis and overall
survival are detailed in Additional file 1: Table S2. The
patients were divided into two groups based on whether
the D-dimer level was above or below the top quartiles
(0.8 μg/L). Patients with high D-dimer levels had a
shorter 3-year DFS, (79%, 95%CI (73.1–84.9)) vs. (69%,
95%CI (59.2–78.8)), DMFS (87%, 95%CI (83.1–90.9)) vs.
(77%, 95%CI (69.2–84.8)), and overall survival (82%, 95%
CI (76.1–87.9)) vs. (76%, 95%CI (66.2–85.8)) (Figure 2).Figure 1 Plasma D-dimer levels are expressed as the median and 5%
according to different variables. (A) Healthy volunteers versus nasophary
metastasis after treatment versus non-distant metastasis (P = 0.002); (C) Non
versus low DNA (<4000 copies/ml) (P = 0.002).Univariate and multivariate analyses of prognostic factors
As shown in Table 2, using 0.8 ug/L as a cut-off value, the
hazard ratios (HRs) and 95% CIs estimated from Cox re-
gression models indicated that the D-dimer level was
strongly associated with DFS, DMFS, and OS (HR, 1.88;
95% CI, 1.28 to 2.77), (HR, 2.16; 95%CI, 1.38 to 3.36) and
(HR, 1.98; 95%CI, 1.29 to 3.04), respectively. In addition to
elevated D-dimer levels, the UICC TNM classification,
high EBV DNA and elevated CRP levels (1.61 mg/L) were
significantly associated with DFS, DMFS, and OS.
Multivariate analysis indicated that elevated D-dimer
levels were a highly significant predictor for DFS, DMFS,
and OS, independent of EBV DNA level, LDH level,
CRP levels, UICC TNM staging, smoking status, and treat-
ment type (Table 3).
Prognostic significance of D-dimer within the UICC TNM
classification, and patients with high or low EBVDNA level
Given the independent prognostic significance of ele-
vated D-dimer levels in NPC patients, we evaluated
the discrimination power of elevated D-dimer levels in
early-stage and advanced-stage patients. Compared to
patients with low D-dimer levels, patients with early-
stage and advanced-stage disease with elevated D-dimer
levels had shorter DFS, DMFS, and OS (Figure 3).
Consistent with previous reports [10,29], we chose
4000 copies/ml to define the low and high pre-treatment-95% percentile in patients with nasopharyngeal carcinoma
ngeal carcinoma patients; (B) Nasopharyngeal carcinoma with distant
-survivors versus survivors (P = 0.002); (D) High DNA (≥4000 copies/ml)
Figure 2 Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of the entire NPC
population according to pre-treatment D-dimer levels (n = 717).
Table 2 Univariate Cox proportional hazards regression analysis
Characteristic DFS (n = 717) DMFS (n = 717) OS (n = 717)
HR 95% CI P HR 95% CI P HR 95% CI P
Age, (≥47 vs. < 47 years) 0.73 0.51 to 1.06 0.100 0.87 0.56 to 1.33 0.517 0.85 0.56 to 1.29 0.444
Male vs. Female 1.08 0.71 to 1.65 0.726 1.48 0.86 to 2.54 0.162 0.92 0.64 to 1.65 0.922
Histology, WHO type (III vs. II) 0.95 0.42 to 2.53 0.949 0.69 0.28 to 1.70 0.689 1.78 0.56 to 5.62 0.328
ECOG (2 vs. 0–1) 1.10 0.15 to 7.85 0.927 1.05 0.36 to 6.53 0.596 1.25 0.14 to 8.99 0.824
Clinical stage (III-IV) vs. (I-II) 3.05 1.34 to 6.94 0.008 4.43 1.40 to 14.01 0.011 2.56 1.04 to 6.31 0.041
Tumour stage (T3-4 vs. T1-2) 1.47 0.93 to 2.31 0.100 1.65 0.94 to 2.88 0.08 1.32 0.80 to 2.18 0.286
Node stage (N2-3 vs. N0-1) 1.72 1.19 to 2.48 0.004 2.19 1.40 to 3.42 0.001 1.75 1.16 to 2.66 0.008
Chemoradiotherapy (yes v no) 1.94 0.90 to 4.17 0.089 1.58 0.69 to 3.63 0.279 1.59 0.70 to 3.64 0.27
IMRT vs. 2DRT/3DCRT 0.55 0.38 to 0.80 0.002 0.66 0.42 to 1.04 0.071 0.88 0.57 to 1.34 0.537
High DNA Vs. Low DNA 2.97 2.02 to 4.36 < 0.001 3.69 2.30 to 5.91 < 0.001 3.50 2.23 to 5.50 < 0.001
CRP, mg/L (≥1.61vs. < 1.61) 1.43 0.99 to 2.06 0.055 1.83 1.18 to 2.84 0.007 1.87 1.23 to 2.85 0.003
VCA-IgA (≥1:80 vs. < 1:80) 1.39 0.91 to 2.13 0.127 1.32 0.81 to 2.16 0.267 0.95 0.64 to 1.61 0.952
EA-IgA (≥1:10 vs. < 1:10) 1.23 0.85 to 1.77 0.282 1.17 0.76 to 1.81 0.477 0.99 0.66 to 1.50 0.977
LDH, U/L (≥167 vs. < 167) 1.41 0.98 to 2.04 0.064 1.67 1.07 to 2.59 0.002 1.38 0.92 to 2.08 0.125
D-dimer, ug/L (≥0.8 vs. < 0.8) 1.88 1.28 to 2.77 0.001 2.16 1.38 to 3.36 0.001 1.98 1.29 to 3.04 0.002
WBC, 109/L (≥6.7 vs. < 6.7) 1.06 0.90 to 1.25 0.753 1.17 0.76 to 1.9 0.481 1.08 0.72 to 1.62 0.709
Neutrophil, 109/L (≥4.1 vs. < 4.1) 1.09 0.76 to 1.56 0.658 1.03 0.67 to 1.57 0.9 1.24 0.82 to 1.87 0.308
HGB, g/l (≥143.8 vs. < 143.8) 0.87 0.61 to 1.25 0.463 0.82 0.53 to 1.25 0.35 0.77 0.51 to 1.16 0.207
PLT, 109/L (≥227 vs. < 227) 1.13 0.79 to 1.62 0.511 1.08 0.71 to 1.66 0.712 1.23 0.82 to 1.84 0.33
Smoking (yes vs. no) 1.27 0.88 to 1.84 0.196 1.59 1.04 to 2.44 0.033 1.22 0.81 to 1.84 0.346
Chronic HBV Infection (yes vs. no) 1.00 0.84 to 1.18 0.953 1.02 0.84 to 1.23 0.881 0.97 0.80 to 1.18 0.969
cardiovascular disease (yes v no) 1.16 0.61 to 2.22 0.653 1.28 0.62 to 2.67 0.5 1.64 0.79 to 3.41 0.184
Diabetes mellitus (yes v no) 0.94 0.85 to 1.05 0.286 0.97 0.87 to 1.08 0.592 0.94 0.84 to1.05 0.248
family history of NPC (yes v no) 1.14 0.61 to 2.11 0.686 1.13 0.55 to 2.35 0.735 1.14 0.92 to 1.41 0.241
Abbreviations: ECOG Eastern Cooperative Oncology Group, 2DRT two-dimensional radiotherapy, 3DCRT three-dimensional conformal radiotherapy,
IMRT intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000 copies/ml,
VCA viral capsid antigen. IgA immunoglobulin A, EA early antigen, LDH Serum Lactate Dehydrogenase Levels, CRP high-sensitivity C-reactive protein, WBC White blood
cell, HGB haemoglobin, PLT platelet, NPC nasopharyngeal carcinoma. DFS disease-free survival, DMFS metastasis-free survival, OS overall survival.
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Table 3 Multivariate Cox proportional hazards regression analysis
Characteristic DFS (n = 717) DMFS (n = 717) OS (n = 717)
HR 95% CI P HR 95% CI P HR 95% CI P
Tumour stage (T3-4 vs. T1-2) 1.23 0.76 to 1.99 0.395 1. 36 0.76 to 2.45 0.305 1.04 0.61 to 1.79 0.88
Node stage (N2-3 vs. N0-1) 1.14 0.76 to 1.71 0.516 1.43 0.88 to 2.33 0.148 1.08 0.68 to 1.72 0.756
Chemoradiotherapy (yes vs. no) 1.23 0.55 to 2.74 0.621 0.84 0.40 to 2.02 0.7 0.89 0.36 to 2.18 0.793
IMRT vs. 2DRT/3DCRT 0.62 0.42 to 0.90 0.013 0.76 0.48 to 1.21 0.246 0.99 0.64 to 1.52 0.954
High DNA vs. Low DNA 2.41 1.59 to 3.64 < 0.001 2.77 1.66 to 4.62 < 0.001 3.06 1.87 to 5.02 < 0.001
CRP, mg/L (≥1.61 vs. < 1.61) 1.14 0.78 to 1.68 0.495 1.35 0.85 to 2.14 0.21 1.48 0.95 to 231 0.082
LDH, U/L (≥167 vs. < 167) 1.22 0.84 to 1.77 0.290 1.35 0.86 to 2.11 0.189 1.23 0.81 to 1.86 0.34
D-dimer, ug/L (≥0.8 vs. < 0.8) 1.60 1.08 to 2.37 0.020 1.79 1.13 to 2.82 0.013 1.58 1.02 to 2.45 0.043
Smoking (yes vs. no) 1.26 0.87 to 1.82 0.216 1.58 1.03 to 2.43 0.036 1.35 0.89 to 2.06 0.159
Abbreviations: ECOG Eastern Cooperative Oncology Group, 2DRT two-dimensional radiotherapy, 3DCRT three-dimensional conformal radiotherapy,
IMRT intensity-modulated radiotherapy, Low DNA denotes a low EBV DNA level of <4000 copies/ml, High DNA denotes a high EBV DNA level of ≥4000 copies/ml,
LDH Serum Lactate Dehydrogenase Levels, CRP high-sensitivity C-reactive protein, DFS disease-free survival, DMFS metastasis-free survival, OS overall survival.
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high EBV DNA subgroup with elevated D-dimer levels
had a worse DFS, DMFS, and OS compared with the pa-
tients with low D-dimer levels. For patients with low
EBV DNA levels, there was no difference in DFS, DMFS,
and OS between the patients with low or high D-dimer
levels (Figure 4).Figure 3 Kaplan-Meier curves of disease-free survival (A), distant met
with early stage (I + II, n = 96), and disease-free survival (D), distant m
with advanced stage (III + IV, (n = 621)), according to pre-treatment DDiscussion
To our knowledge, this is the first large-scale cohort
study examining the association between coagulation
and survival in nasopharyngeal carcinoma patients. The
activation of coagulation in cancer patients is widely im-
plicated in both tumour progression and the develop-
ment of thrombosis [31]. High levels of plasma D-dimerastasis-free survival (B), and overall survival (C) of NPC patients
etastasis-free survival (E), and overall survival (F) of NPC patients
-dimer levels.
Figure 4 Kaplan-Meier curves of disease-free survival (A), distant metastasis-free survival (B), and overall survival (C) of NPC patients
with plasma EBV DNA < 4000c copies/ml (n = 411), and disease-free survival (D), distant metastasis-free survival (E), and overall
survival (F) of NPC patients with the plasma EBV DNA ≥ 4000 copies/ml, according to pre-treatment D-dimer levels.
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malignant diseases, including lung pancreas, prostate,
gastric, colorectal, and breast cancer [19,20,32,33]. Re-
cently, Liu et al. [32] demonstrated that elevated plasma
D-dimer was correlated with depth of invasion, lymph
node metastasis, peritoneal dissemination, distant metas-
tasis, tumour size, TNM stage, and worse overall survival
in gastric cancer. Interestingly, according to our findings,
the D-dimer plasma level is a marker of endogenous
fibrinolysis that can be used to evaluate hypercoagula-
bility, and it has both clinical and prognostic signifi-
cance in nasopharyngeal carcinoma patients. With a
median follow-up of 3 years, the HR of DFS, DMFS, and
OS in cancer patients with the highest D-dimer levels in
the total study population (D-dimer levels ranging from
3rd quartile to the maximum level) was two-fold higher
than patients with D-dimer levels ranging from the
minimum to the 1st quartile. Using the 3rd quartile
(0.8 μg/mL) as the final cut-off, multivariate analysis
revealed that pre-treatment D-dimer levels were a signifi-
cant, independent prognostic factor for predicting recur-
rence, distant metastasis, and death. This effect was
independent of EBV DNA level, LDH level, CRP levels,
UICC TNM staging, smoking status, and treatment type
(Table 3).Plasma EBV DNA has been demonstrated to be corre-
lated with tumour burden [34], TNM stage [35], re-
sponse to chemoradiotherapy [36-38], and survival in
NPC patients [8,10,29]. Plasma EBV DNA is now a use-
ful biomaker for the clinical management of NPC pa-
tients, and it is considered the most attractive potential
biomarker [37]. However, for NPC patients with EBV
DNA ≥4000 copies/ml, patients with D-dimer ≥ 0.8 μg/L
still have a shorter DFS, DMFS, and OS compared to pa-
tients with D-dimer < 0.8 μg/L. However, this result does
not apply to patients with EBV DNA < 4000 copies/ml.
Although the magnitude of the predictive value of EBV
DNA was superior to that of D-dimer, it is not sufficient
to use plasma EBV DNA alone for prognostic stratifica-
tion due to the heterogeneity of NPC patients. Notably,
patients in the high EBV DNA subgroup with high
plasma D-dimer levels had a worse disease-free survival,
distant metastasis-free survival, and overall survival. These
results indicate that EBV DNA alone is insufficient to
complement the TNM classification, and plasma D-dimer
levels represent a complementary marker to EBV DNA
leves for the prediction of NPC patient prognosis.
Although the mechanism underlying D-dimer-mediated
NPC progression of remains unknown, it is likely due
to different D-dimer signalling pathways or biological
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and NPC progression may be explained by abnormalities
in haemostasis and fibrinolysis during tumour pathogen-
esis. The activation of coagulation is the result of increased
tissue factor expression, which leads to fibrin deposition.
Tumour cells also express tissue factors, and they might
contribute to a variety of pathological processes, such as
VTE, metastatic spread, tumour growth, and tumour
angiogenesis [39].
Interestingly, elevated D-dimer levels still predicted
a poorer DFS, DMFS, and OS for early and advanced
stage NPC patients in both high and low EBV DNA sub-
groups, independent of TNM staging (Figure 3). Recent
advancements in NPC patient classification and NPC
molecular alterations have been made, including micro-
RNA signatures [40] and the NPC-SVM classifier [41].
However, these developments require expensive and
complicated procedures, and rapid clinical implementa-
tion was difficult to achieve in a short time. Plasma
D-dimer levels are established, routinely measured blood-
based parameters that are reproducibly detected without
additional laborious efforts before use in clinical applica-
tions. These findings have great clinical relevance because
D-dimer subgroups with different prognoses in defined
TNM stages indicate the need for individual treatment for
NPC patients in the future. The association between pre-
treatment D-dimer levels and TNM stage may be helpful
for screening NPC patients. If a patient displays an abnor-
mally high D-dimer level before treatment, they may re-
quire more intensive systemic approaches to improve the
treatment outcome.
However, there are still some limitations to the present
study, such as the single D-dimer measurements re-
corded from a single centre. Another limitation of this
study is that we neglected to collect data for venous
thromboembolism (VTE) events. High D-dimer levels have
previously been reported to predict VTE in cancer patients
[42,43], and both D-dimer and VTE are negative prognos-
tic factors for cancer patients [33]. The third limitation was
the short follow-up time, and additional patient data will
be reported after the the 5 year follow-up.
Conclusions
In summary, we demonstrated that pre-treatment D-dimer
levels can reflect hypercoagulability in NPC patients.
Our results suggest that D-dimer is a promising prog-
nostic biomarker associated with disease-free, distant
metastasis-free and overall survival. D-dimers repre-
sent a widely available potential biomarker, and the
assays to detect D-dimer levels have been sufficiently
validated. D-dimers should be considered for routine
testing in NPC patients. A prospective study is needed
to explore this area, and our results should be vali-
dated using other datasets.Additional file
Additional file 1: Figure S1. Cumulative probability of disease-free
survival (DFS), distant metastasis-free survival (DMFS), and overall survival
in the total study population (n=717). (1) Patients in the 1st group, with
D-dimer levels ranging from minimum to 1st quartile (0.00 to 0.3 μg/mL)
levels in the total study population, are compared to (2) those with
D-dimer levels in the 2nd group, with levels between the 1st and 2nd
quartiles [0.30 to 0.50μg/mL], (3) and those in the 3rd group, with levels
between the 2nd and 3rd quartiles [0.50 to 0.80μg/mL], and (4) the 4th
group, with D-dimer levels ranging from the 3rd quartile to maximum
[0.80to 37.2μg/mL] of D-dimer levels in the study population. The total
numbers of patients with D-dimer levels in the 1st, 2nd, 3rd and 4th
groups at study institute were 212, 202, 148 and 155, respectively. Table S1.
D-dimer Relationships. Table S2. Prognostic value of D-dimer for DFS, DMFS,
and OS by Quartiles.
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